CN109498632A - A kind of composite sulfamonomethoxine microcapsule formulation and preparation method thereof - Google Patents
A kind of composite sulfamonomethoxine microcapsule formulation and preparation method thereof Download PDFInfo
- Publication number
- CN109498632A CN109498632A CN201811624550.5A CN201811624550A CN109498632A CN 109498632 A CN109498632 A CN 109498632A CN 201811624550 A CN201811624550 A CN 201811624550A CN 109498632 A CN109498632 A CN 109498632A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- sustained release
- release agent
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a kind of composite sulfamonomethoxine microcapsule formulations, it is characterized by: preparing in raw material and containing in terms of mass fraction: 5~20 parts of daimeton, 1~4 part of trimethoprim, 55~65 parts of sustained release agent, 4~10 parts of organic solvent, 10~30 parts of filler.The composite sulfamonomethoxine pre-mixing agent that the present invention prepares can inhibit most of gram-positive bacterias and certain negative bacteriums, and systemic infection caused by prevention and control pig toxoplasm, Escherichia coli, Pasteurella, streptococcus, haemophilus parasuis, eperythrozoon, Actinobacillus etc. has good effect；Long lasting benefits are obvious, and antibacterial activity and curative effect greatly enhance, and simple production process has saved production cost, are suitble to industrialized production.
Description
Technical field
The present invention relates to a kind of composite sulfamonomethoxine microcapsule formulations and preparation method thereof.
Background technique
Daimeton (Sulfamonomethoxine, SMM) is a kind of application and its extensive sulfa drug, is had
Has a broad antifungal spectrum, property are stable, price is cheap and the advantage available there are many preparation.It may interfere with the synthesis of bacterium folic acid
And its growth and breeding is influenced, to inhibit most of gram-positive bacterias and certain negative bacteriums, prevention and control pig toxoplasm,
Systemic infection caused by Escherichia coli, Pasteurella, streptococcus, haemophilus parasuis, eperythrozoon, Actinobacillus etc.
With good effect.With double pharmacological action can antibacterial and antiprotozoan, it is sensitive to pig coccidia, toxoplasm.Although
Antibiotic develops rapidly in recent years, and sulfa drugs is not eliminated not only, and still occupies important ground in antimicrobial
Position, especially Trimethoprim occur after, be used in combination with Trimethoprim, make daimeton antibacterial activity and
Curative effect greatly enhances, or even becomes fungicide from bacteriostatic agent.The wherein antibacterial action of daimeton and pre- bacteriological protection sense
It is most strong in sulfa drugs to contaminate efficiency.It absorbs well, blood concentration is high, and the maintenance effect time nearly 24 hours, plasma protein combined
Rate is high, and acetyl rate is very low, thus effective concentration duration best a kind of effective agent in body fluid, and toxicity is low, is not easy to draw
Play crystalluria and blood urine.When whole body or localized bacterial infection occurs to farm, works well, can be used for various sensitive bacterias
Caused respiratory tract, alimentary canal, urethral infection and globidiosis, toxoplasmosis, eperythrozoonosis etc. solve many support
The problem of growing field production.
Trimethoprim (TMP) belongs to bacteriostatic agent, is lipophilicity weak base, chemical structure category pyrimethamine class.It is uncommon to large intestine angstrom
Bacterium, Klebsiella, proteus mirabilis, Salmonella, Shigella all have antibacterial activity, to streptococcus pneumonia, stranguria syndrome
Neisseria, the antibacterial action of Neisseria meningitidis are unobvious, to pseudomonas aeruginosa without effect.TMP mechanism of action is that interference is thin
The folic acid metabolism of bacterium.The predominantly activity of the dihyrofolate reductase of selective depression bacterium, prevents dihydrofoilic acid from being reduced to
Tetrahydrofolic acid, and the chief component that folic acid is Nucleic acid is synthesized, therefore this product prevents bacterial nucleic acid and albumen
The synthesis of matter, to inhibit the growth and breeding of bacterium, and the combination of TMP and the dihyrofolate reductase of bacterium is compared with to lactation
Class animal ferment is tightly combined 50,000~60,000 times.TMP and sulfa drug, which share, can make the folic acid anabolism of bacterium by dual resistance
It is disconnected, there is synergistic effect, enhance sulfa drug antibacterial activity, and bacteriostasis can be made to switch to bactericidal effect, reduces antibody-resistant bacterium and produce
It is raw.
Traditional formulation method adjusts pH value after dissolving by heating using organic solvent, organic solvent is mostly used propylene glycol or poly- second
Glycol 400 and pyrrolidones etc. are single or are used in mixed way, but dosage is up to 40~80%.Such method not only expends largely
Organic solvent, and a large amount of organic solvent is also easy to cause biggish irritation.
Summary of the invention
The purpose of the present invention is to provide a kind of composite sulfamonomethoxine microcapsule formulations and preparation method thereof, solve existing
The problem of some methods largely expend organic solvent and easily cause the stimulation of body.
The technical solution used in the present invention is:
A kind of composite sulfamonomethoxine microcapsule formulation is prepared in raw material and is contained in terms of mass fraction: first between sulfanilamide (SN)
5~20 parts of oxygen pyrimidine, 1~4 part of trimethoprim, 55~65 parts of sustained release agent, 4~10 parts of organic solvent, 10~30 parts of filler.
Further, it in terms of mass fraction, prepares in raw material and contains: 10 parts of daimeton, trimethoprim 2.1
Part, 61.9 parts of sustained release agent, 6 parts of organic solvent, 20 parts of filler.
Further, sustained release agent is monoglyceride.
Further, organic solvent PEG4000.
Further, filler is the mixture of starch and precipitated calcium carbonate.
Further, the mass ratio of starch and precipitated calcium carbonate is 1:1.
The preparation method of above-mentioned composite sulfamonomethoxine microcapsule formulation, it is characterised in that: the following steps are included:
(1) it by sustained release agent, organic solvent investment emulsion tank, heats, stirring keeps material completely melt and dissolved；
(2) after material is completely melt and dissolved, stirring investment sustained release agent is opened, is stirred evenly, investment trimethoprim, methoxy between sulfanilamide (SN)
Pyrimidine, to be mixed uniform, opening emulsifier keeps emulsifying materials uniform；
(3) low velocity spray granulator is opened, then the raw material quantitative that stirs evenly is added in low velocity spray granulator, from cold
But all particles are collected in tank to obtain the final product.
The beneficial effects of the present invention are:
The invention discloses a kind of composite sulfamonomethoxine microcapsule formulations and preparation method thereof, and what the present invention prepared answers
Square daimeton pre-mixing agent can inhibit most of gram-positive bacterias and certain negative bacteriums, prevention and control pig arch
Whole body caused by body, Escherichia coli, Pasteurella, streptococcus, haemophilus parasuis, eperythrozoon, Actinobacillus etc. is sexy
Dye has good effect；Long lasting benefits are obvious, and antibacterial activity and curative effect greatly enhance, simple production process, saved production
Cost is suitble to industrialized production.
Specific embodiment
The application is described in further detail below with reference to embodiment, it is necessary to it is indicated herein to be, it is real in detail below
The mode of applying is served only for that the application is further detailed, and should not be understood as the limitation to the application protection scope, the field
Technical staff some nonessential modifications and adaptations can be made to the application according to above-mentioned application content.
Embodiment 1
A kind of composite sulfamonomethoxine microcapsule formulation is prepared from the following materials in terms of mass fraction: between sulfanilamide (SN)
10.0 parts by weight of Sulfamonomethoxine, 2.1 parts by weight of trimethoprim, 61.9 parts by weight of sustained release agent, 6.0 parts by weight of organic solvent, filling
20.0 parts by weight of agent.
Sustained release agent is monoglyceride, organic solvent PEG4000, and filler is the mixture of starch and precipitated calcium carbonate, two
Person's mixing mass ratio is 1:1.
Its preparation step are as follows:
1) emulsion tank water heating temperature is set as 95 DEG C, and 61.9 parts by weight monoglycerides, 6.0 parts by weight PEG4000 are put into
In emulsion tank, 80 DEG C or so are risen to temperature of charge, stirring is opened, keeps material completely melt and dissolved.
2) after material is completely melt and dissolved, emulsion tank water heating temperature is adjusted to 82 DEG C, opens stirring 20.0 parts by weight of investment
Starch, precipitated calcium carbonate put into 2.1 parts by weight trimethoprim, 10.0 parts by weight to material stirring to without situation is significantly built up
Daimeton, after material stirring to without after significantly building up situation, opening emulsifier 4 times emulsifies material completely uniformly,
Water temperature is adjusted to 85 DEG C, temperature of charge is controlled at 85 DEG C or so.
3) low velocity spray granulation electromechanical source is opened, setting speed presses operation key, after machine normal operation, under opening
Expect valve, control flow valve do not got rid of with material tank skin be it is best, after the completion of spraying, close blanking valve, close and make by spraying
Grain electromechanical source.
4) material after the assay was approved, was subjected to linear vibrating screen selection and needs granularity material.
Embodiment 2
A kind of composite sulfamonomethoxine microcapsule formulation is prepared from the following materials in terms of mass fraction: between sulfanilamide (SN)
5.0 parts by weight of Sulfamonomethoxine, 4.0 parts by weight of trimethoprim, 55.0 parts by weight of sustained release agent, 10.0 parts by weight of organic solvent, filling
26.0 parts by weight of agent.
Sustained release agent is monoglyceride, organic solvent PEG4000, and filler is the mixture of starch and precipitated calcium carbonate, two
Person's mixing mass ratio is 1:1.
Its preparation step are as follows:
1) emulsion tank water heating temperature is set as 95 DEG C, and 55.0 parts by weight monoglycerides, 10.0 parts by weight PEG4000 are put into
In emulsion tank, 80 DEG C or so are risen to temperature of charge, stirring is opened, keeps material completely melt and dissolved.
2) after material is completely melt and dissolved, emulsion tank water heating temperature is adjusted to 82 DEG C, opens stirring 26.0 parts by weight of investment
Starch, precipitated calcium carbonate put into 4.0 parts by weight trimethoprim, 5.0 parts by weight to material stirring to without situation is significantly built up
Daimeton, after material stirring to without after significantly building up situation, opening emulsifier 4 times emulsifies material completely uniformly,
Water temperature is adjusted to 85 DEG C, temperature of charge is controlled at 85 DEG C or so.
3) low velocity spray granulation electromechanical source is opened, setting speed presses operation key, after machine normal operation, under opening
Expect valve, control flow valve do not got rid of with material tank skin be it is best, after the completion of spraying, close blanking valve, close and make by spraying
Grain electromechanical source.
4) material after the assay was approved, was subjected to linear vibrating screen selection and needs granularity material.
Embodiment 3
A kind of composite sulfamonomethoxine microcapsule formulation is prepared from the following materials in terms of mass fraction: between sulfanilamide (SN)
20.0 parts by weight of Sulfamonomethoxine, 1.0 parts by weight of trimethoprim, 65.0 parts by weight of sustained release agent, 4.0 parts by weight of organic solvent, filling
10.0 parts by weight of agent.
Sustained release agent is monoglyceride, organic solvent PEG4000, and filler is the mixture of starch and precipitated calcium carbonate, two
Person's mixing mass ratio is 1:1.
Its preparation step are as follows:
1) emulsion tank water heating temperature is set as 95 DEG C, and 65.0 parts by weight monoglycerides, 4.0 parts by weight PEG4000 are put into
In emulsion tank, 80 DEG C or so are risen to temperature of charge, stirring is opened, keeps material completely melt and dissolved.
2) after material is completely melt and dissolved, emulsion tank water heating temperature is adjusted to 82 DEG C, opens stirring 10.0 parts by weight of investment
Starch, precipitated calcium carbonate put into 1.0 parts by weight trimethoprim, 20.0 parts by weight to material stirring to without situation is significantly built up
Daimeton, after material stirring to without after significantly building up situation, opening emulsifier 4 times emulsifies material completely uniformly,
Water temperature is adjusted to 85 DEG C, temperature of charge is controlled at 85 DEG C or so.
3) low velocity spray granulation electromechanical source is opened, setting speed presses operation key, after machine normal operation, under opening
Expect valve, control flow valve do not got rid of with material tank skin be it is best, after the completion of spraying, close blanking valve, close and make by spraying
Grain electromechanical source.
4) material after the assay was approved, was subjected to linear vibrating screen selection and needs granularity material.
Product uniformity testing
Rise national standard according to " veterinary drug national standard compilation "-veterinary drug provincial standard to be detected, as a result as follows:
It can be seen from the above result that the product mix uniformity≤15.0 in Examples 1 to 3, containing daimeton and
Trimethoprim should be the 91.0%~110.0% of labelled amount.
Veterinary clinic application effect
Case source: technical staff acquires clinical natural occurrence case, respectively pig in the area such as Yunfu, Zhaoqing, Zhengzhou
Streptococcosis 545, toxoplasmosis 402, colibacillosis 652, pasteurellosis 527, streptococcosis 472,
Haemophilus parasuis 324, eperythrozoonosis 428, chicken coccidiasis 1985.
Case diagnosis: with natural cases according to epidemiology, clinical symptoms, pathological change, Laboratory Diagnosed.Comprehensive point
Analysis, is made a definite diagnosis.
Implementation process: case selection is carried out by test requirements document by this seminar technical staff and implements to treat, and records examination
Test result.
Result judgement: natural cases are according to dosage administered with the course for the treatment of, is observed in 7 days, is paid a return visit and record the state of an illness.
Cure: affected animal illness completely disappears after medication 2~3 times, and spirit, body temperature, appetite are restored normally, and urine excrement is also just
Often.
Effective: affected animal illness disappears substantially after medication 2~3 times, and spirit, body temperature, appetite make moderate progress, and urine excrement is also just
Often.
Invalid: affected animal illness does not disappear after medication 2~3 times, and sb.'s illness took a turn for the worse or dead, and urine excrement is also normal.
The clinical therapeutic efficacy of product is as shown in the table in embodiment 1:
Product has good therapeutic effect in embodiment 1 as can be seen from the above table, to Streptococcus suis, toxoplasmosis,
Streptococcosis, the effective percentage of the diseases such as chicken coccidiasis is 94% or more, to colibacillosis, pasteurellosis, eperythrozoon
The effective percentage such as disease reach 92% or more, and cure rate is 92% or more.
Comparative example 1
A kind of daimeton pulvis, the preparation method is as follows:
1) 10.0 parts by weight of daimeton, the talcum powder of trimethoprim 2.1 parts by weight and 77.9 parts by weight are weighed
It is added in agitator tank and is uniformly mixed；
2) weigh 20.0 parts by weight starch and precipitated calcium carbonate mixture be added agitator tank between sulfanilamide (SN) methoxy it is phonetic
Pyridine, trimethoprim are uniformly mixed.
Comparative example 2
A kind of composite sulfamonomethoxine microcapsule formulation is prepared from the following materials in terms of mass fraction: between sulfanilamide (SN)
10.0 parts by weight of Sulfamonomethoxine, 2.1 parts by weight of trimethoprim, 61.9 parts by weight of sustained release agent, 6.0 parts by weight of organic solvent, filling
20.0 parts by weight of agent.
Sustained release agent is light carburetion, and organic solvent PEG4000, filler is the mixture of starch and precipitated calcium carbonate.
Its preparation step are as follows:
1) emulsion tank water heating temperature is set as 95 DEG C, and the light carburetion of 61.9 parts by weight, 6.0 parts by weight PEG4000 are put into
In emulsion tank, 80 DEG C or so are risen to temperature of charge, stirring is opened, keeps material completely melt and dissolved.
2) after material is completely melt and dissolved, emulsion tank water heating temperature is adjusted to 82 DEG C, opens stirring 20.0 parts by weight of investment
Starch, precipitated calcium carbonate put into 2.1 parts by weight trimethoprim, 10.0 parts by weight to material stirring to without situation is significantly built up
Daimeton, after material stirring to without after significantly building up situation, opening emulsifier 4 times emulsifies material completely uniformly,
Water temperature is adjusted to 85 DEG C, temperature of charge is controlled at 85 DEG C or so.
3) low velocity spray granulation electromechanical source is opened, setting speed presses operation key, after machine normal operation, under opening
Expect valve, control flow valve do not got rid of with material tank skin be it is best, after the completion of spraying, close blanking valve, close and make by spraying
Grain electromechanical source.
4) material after the assay was approved, was subjected to linear vibrating screen selection and needs granularity material.
Comparative example 3
A kind of composite sulfamonomethoxine microcapsule formulation is prepared from the following materials in terms of mass fraction: between sulfanilamide (SN)
10.0 parts by weight of Sulfamonomethoxine, 2.1 parts by weight of trimethoprim, 61.9 parts by weight of sustained release agent, 6.0 parts by weight of organic solvent, filling
20.0 parts by weight of agent.
Sustained release agent is tween, and organic solvent PEG4000, filler is the mixture of starch and precipitated calcium carbonate.
Its preparation step are as follows:
1) emulsion tank water heating temperature is set as 95 DEG C, and 61.9 parts by weight tweens, 6.0 parts by weight PEG4000 are put into cream
Change in cylinder, rises to 80 DEG C or so to temperature of charge, open stirring, keep material completely melt and dissolved.
2) after material is completely melt and dissolved, emulsion tank water heating temperature is adjusted to 82 DEG C, opens stirring 20.0 parts by weight of investment
Starch, precipitated calcium carbonate put into 2.1 parts by weight trimethoprim, 10.0 parts by weight to material stirring to without situation is significantly built up
Daimeton, after material stirring to without after significantly building up situation, opening emulsifier 4 times emulsifies material completely uniformly,
Water temperature is adjusted to 85 DEG C, temperature of charge is controlled at 85 DEG C or so.
3) low velocity spray granulation electromechanical source is opened, setting speed presses operation key, after machine normal operation, under opening
Expect valve, control flow valve do not got rid of with material tank skin be it is best, after the completion of spraying, close blanking valve, close and make by spraying
Grain electromechanical source.
4) material after the assay was approved, was subjected to linear vibrating screen selection and needs granularity material.
Comparative example 4
A kind of composite sulfamonomethoxine microcapsule formulation is prepared from the following materials in terms of mass fraction: between sulfanilamide (SN)
10.0 parts by weight of Sulfamonomethoxine, 2.1 parts by weight of trimethoprim, 61.9 parts by weight of sustained release agent, 6.0 parts by weight of organic solvent, filling
20.0 parts by weight of agent.
Sustained release agent is paraffin, and organic solvent PEG4000, filler is the mixture of starch and precipitated calcium carbonate.
Its preparation step are as follows:
1) emulsion tank water heating temperature is set as 95 DEG C, and 61.9 parts by weight paraffin, 6.0 parts by weight PEG4000 are put into cream
Change in cylinder, rises to 80 DEG C or so to temperature of charge, open stirring, keep material completely melt and dissolved.
2) after material is completely melt and dissolved, emulsion tank water heating temperature is adjusted to 82 DEG C, opens stirring 20.0 parts by weight of investment
Starch, precipitated calcium carbonate put into 2.1 parts by weight trimethoprim, 10.0 parts by weight to material stirring to without situation is significantly built up
Daimeton, after material stirring to without after significantly building up situation, opening emulsifier 4 times emulsifies material completely uniformly,
Water temperature is adjusted to 85 DEG C, temperature of charge is controlled at 85 DEG C or so.
3) low velocity spray granulation electromechanical source is opened, setting speed presses operation key, after machine normal operation, under opening
Expect valve, control flow valve do not got rid of with material tank skin be it is best, after the completion of spraying, close blanking valve, close and make by spraying
Grain electromechanical source.
4) material after the assay was approved, was subjected to linear vibrating screen selection and needs granularity material.
Comparative example 5
A kind of composite sulfamonomethoxine microcapsule formulation is prepared from the following materials in terms of mass fraction: between sulfanilamide (SN)
10.0 parts by weight of Sulfamonomethoxine, 2.1 parts by weight of trimethoprim, 61.9 parts by weight of sustained release agent, 6.0 parts by weight of organic solvent, filling
20.0 parts by weight of agent.
Sustained release agent is monoglyceride, and organic solvent is petroleum ether, and filler is the mixture of starch and precipitated calcium carbonate.
Its preparation step are as follows:
1) emulsion tank water heating temperature is set as 95 DEG C, and 61.9 parts by weight monoglycerides, 6.0 parts by weight petroleum ethers are put into cream
Change in cylinder, rises to 80 DEG C or so to temperature of charge, open stirring, keep material completely melt and dissolved.
2) after material is completely melt and dissolved, emulsion tank water heating temperature is adjusted to 82 DEG C, opens stirring 20.0 parts by weight of investment
Starch, precipitated calcium carbonate put into 2.1 parts by weight trimethoprim, 10.0 parts by weight to material stirring to without situation is significantly built up
Daimeton, after material stirring to without after significantly building up situation, opening emulsifier 4 times emulsifies material completely uniformly,
Water temperature is adjusted to 85 DEG C, temperature of charge is controlled at 85 DEG C or so.
3) low velocity spray granulation electromechanical source is opened, setting speed presses operation key, after machine normal operation, under opening
Expect valve, control flow valve do not got rid of with material tank skin be it is best, after the completion of spraying, close blanking valve, close and make by spraying
Grain electromechanical source.
4) material after the assay was approved, was subjected to linear vibrating screen selection and needs granularity material.
Product uniformity testing
Rise national standard according to " veterinary drug national standard compilation "-veterinary drug provincial standard to be detected, as a result as follows:
According to result above it is found that the product uniformity being prepared is remote after the sustained release agent in composition of raw materials is replaced
Not as good as the uniformity of product in Examples 1 to 3.And the product slow release effect in comparative example 2 is poor, daimeton and
Trimethoprim release does not come out.
In comparative example 3, although the product uniformity can achieve defined standard, tween price is higher, will increase life
Produce cost.
Paraffin is immiscible with PEG4000 in comparative example 4, and material is layered after emulsification.
Make organic solvent with petroleum ether in comparative example 5, the shape of product produced is lack of standardization, and grain is soft.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously
Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to of the invention
Protection scope.
Claims (7)
1. a kind of composite sulfamonomethoxine microcapsule formulation, it is characterised in that: in terms of mass fraction, prepare in raw material and contain
Have: 5~20 parts of daimeton, 1~4 part of trimethoprim, 55~65 parts of sustained release agent, 4~10 parts of organic solvent, filler
10~30 parts.
2. composite sulfamonomethoxine microcapsule formulation according to claim 1, it is characterised in that: in terms of mass fraction,
It, which is prepared in raw material, contains: 10 parts of daimeton, 61.9 parts of sustained release agent, 6 parts of organic solvent, is filled out at 2.1 parts of trimethoprim
Fill 20 parts of agent.
3. composite sulfamonomethoxine microcapsule formulation according to claim 1, it is characterised in that: sustained release agent is single sweet
Rouge.
4. composite sulfamonomethoxine microcapsule formulation according to claim 1, it is characterised in that: organic solvent is
PEG4000。
5. composite sulfamonomethoxine microcapsule formulation according to claim 1, it is characterised in that: filler be starch and
The mixture of precipitated calcium carbonate.
6. composite sulfamonomethoxine microcapsule formulation according to claim 5, it is characterised in that: starch and lightweight carbonic acid
The mass ratio of calcium is 1:1.
7. the preparation method of the described in any item composite sulfamonomethoxine microcapsule formulations of claim 1~6, feature exist
In: the following steps are included:
1) it by sustained release agent, organic solvent investment emulsion tank, heats, stirring keeps material completely melt and dissolved；
2) material completely it is melt and dissolved after, open stirring investment sustained release agent, stir evenly, put into trimethoprim, daimeton,
To be mixed uniform, opening emulsifier keeps emulsifying materials uniform；
3) low velocity spray granulator is opened, then the raw material quantitative stirred evenly is added in low velocity spray granulator, from cooling tank
It is middle to collect all particles to obtain the final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811624550.5A CN109498632B (en) | 2018-12-28 | 2018-12-28 | Compound sulfamonomethoxine microcapsule preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811624550.5A CN109498632B (en) | 2018-12-28 | 2018-12-28 | Compound sulfamonomethoxine microcapsule preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109498632A true CN109498632A (en) | 2019-03-22 |
| CN109498632B CN109498632B (en) | 2021-04-20 |
Family
ID=65756688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811624550.5A Active CN109498632B (en) | 2018-12-28 | 2018-12-28 | Compound sulfamonomethoxine microcapsule preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109498632B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109917071A (en) * | 2019-03-29 | 2019-06-21 | 佛山市正典生物技术有限公司 | A kind of detection method of composite sulfamonomethoxine microcapsule formulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524467A (en) * | 2018-07-02 | 2018-09-14 | 合肥中龙神力动物药业有限公司 | A kind of composite sulfamonomethoxine sodium microcapsule formulation and preparation method thereof |
-
2018
- 2018-12-28 CN CN201811624550.5A patent/CN109498632B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524467A (en) * | 2018-07-02 | 2018-09-14 | 合肥中龙神力动物药业有限公司 | A kind of composite sulfamonomethoxine sodium microcapsule formulation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 林承仪: "兽药新剂型与新技术-微囊化技术", 《兽药与饲料添加剂》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109917071A (en) * | 2019-03-29 | 2019-06-21 | 佛山市正典生物技术有限公司 | A kind of detection method of composite sulfamonomethoxine microcapsule formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109498632B (en) | 2021-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101128114B (en) | 18-membered macrocycles and analogs thereof | |
| Long et al. | Comparison of porous and nano zinc oxide for replacing high-dose dietary regular zinc oxide in weaning piglets | |
| EP3574900B1 (en) | New applications of rifamycin-nitroimidazole coupling molecules | |
| CN108835403A (en) | A kind of sheep full price hybrid particles feed and preparation method thereof | |
| CN108635585A (en) | A kind of pharmaceutical composition for treating senile vahinitis and temperature sensitive slow-releasing gel used and preparation method | |
| WO2017101536A1 (en) | Pharmaceutical composition for preventing and treating arthritis and preparation method thereof | |
| CN109223707A (en) | A kind of uricase external-use gel preparation, preparation method and the usage | |
| WO2006079288A1 (en) | Use of human lysozyme for preparing cosmetics against acne | |
| CN109498632A (en) | A kind of composite sulfamonomethoxine microcapsule formulation and preparation method thereof | |
| CN101229126B (en) | Tinidazole compound nano silver microemulsion antibacterial medicine | |
| CN106278907B (en) | A kind of Syprine Hydrochloride compound | |
| CN102283842A (en) | Compound mequindox florfenicol nanoemulsion antibacterial drug and preparation method thereof | |
| CN107752015A (en) | The composite nutrient food that a kind of all-digestive tract improves | |
| CN103536604B (en) | A kind of wettable sulfamethoxazole trimethoprim powder and preparation method thereof | |
| CN108743534A (en) | A kind of Celastrol or tripterine derivate vesica and preparation method thereof | |
| CN107647114A (en) | A kind of method of pellet addition medicine | |
| CN101152188B (en) | Vitamin D* solid dispersion peridium patch and method for preparing the same | |
| CN103142587B (en) | Amoxicillin sodium-potassium clavulanate pharmaceutical composition and preparation method thereof | |
| JP2007506645A (en) | Use of N-acetyl-D-glucosamine in the manufacture of formulations for antitumor and antimetastasis | |
| CN101648001A (en) | Veterinary compound apramycin sulfate soluble powder and application thereof | |
| CN103536606B (en) | A kind of wettable sulfamethoxydiazine powder and preparation method thereof | |
| CN110327284A (en) | A kind of cefodizime sodium for injection and preparation method thereof | |
| CN108079006A (en) | The preparation method and ivermectin formulation of ivermectin formulation | |
| CN103127129A (en) | Cefuroxime sodium pharmaceutical composition and preparation method thereof | |
| CN103330711B (en) | Flucloxacillin sodium and amoxicillin sodium for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |